Nascent perspectives on COVID-19 treatments

As of June 29th, 2021, the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, has resulted in a global incidence of 181 007 816 cases, with corresponding mortality of 3 927 222 or a mortality rate of 2.2%. Global COVID-19 vaccination efforts have resulted in about 2.97 billion doses administered or approximately 19.4% of the global population. Despite vaccination and other preventative efforts, the ongoing mutation of the COVID-19 virus continues to cause significant morbidity and mortality. Therefore, pharmacologic interventions remain essential in managing severe symptomatic presentation of COVID-19, which includes acute respiratory distress syndrome, severe cytokine storm, and septic shock. This article has reviewed several unique case studies published from August 2020 through June 2021 with the above perspectives.